Association of the Genetic Marker for Abacavir Hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos

Abstract

It is feasible to have a pharmacogenetic program based on HCP5 rs2395029 genotyping as a screening tool with confirmation of HLA-B*5701 carriage by sequenciation, to prevent abacavir hypersensitivity reaction in Mexican patients before initiating abacavir therapy.

In Mexican Mestizos the HCP5 rs2395029 SNP May Be a Genetic Marker for Screening Abacavir Hypersensitivity

“…In their study, the authors cite our work published in Pharmacogenomics [2], and state that we "endorse the original suggestion by Colombo et al to rely on the HCP5 SNP test alone to determine individual susceptibility to abacavir HSR in HIV-positive patients before starting therapy".…”

Investigating the genetic association of HCP5,SPATA2,TNIP1,TNFAIP3 and COG6 with psoriasis in Chinese population

“…Together with the allele HLA-B*5701, HCP5 was reported to be associated with low viral loads in untreated HIV patients (Fellay et al, 2007). But HCP5 was susceptibility to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (Tse et al, 2011;Borgiani et al, 2014) and abacavir hypersensitivity (Sanchez-Giron et al, 2011). HCV was also associated with HCV-associated hepatocellular carcinoma (Lange et al, 2013).…”

HLA and Pharmacogenetics of Drug Hypersensitivity

“…Sequencebased typing or allele-specific PCR are the most definitive means of identifying the presence of HLA-B*5701; however, due to greater ease of use some clinical laboratories choose to perform SNP testing over allele-specific PCR. This method involves SNP typing of rs2395029, a SNP located in the nearby HLA complex P5 gene (HCP5) approximately 100 kb away from HLA-B and has been shown to significantly correlate with the presence of HLA-B*5701 in Caucasians [111,134] and Hispanics [135]. However, it is currently known that HLA-B*5701 is necessary for the development of ABC HSR and therefore caution should be used when using HCP5 rs2395029 as a screening test as there is strong but incomplete LD between HLA-B*5701 and this HCP5 SNP leading to a lower positive-predictive value and also a less than 100% negative-predictive value when compared to HLA-B*5701 specific tests [136].…”